These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 20877608)
21. Percutaneous Tibial Nerve Stimulation in the Treatment of Refractory Idiopathic Overactive Bladder Syndrome: A Retrospective Cohort Study. Frey JN; Vidal A; Krebs J; Christmann C J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959248 [TBL] [Abstract][Full Text] [Related]
22. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome. Yüce T; Dökmeci F; Çetinkaya ŞE Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597 [TBL] [Abstract][Full Text] [Related]
23. Vaginal laser for overactive bladder syndrome. Charalampous I; Tailor VK; Digesu A Int Urogynecol J; 2020 Aug; 31(8):1515-1517. PubMed ID: 32399906 [TBL] [Abstract][Full Text] [Related]
24. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle. Dokmeci F; Cetinkaya SE; Seval MM; Dai O Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584 [TBL] [Abstract][Full Text] [Related]
25. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects. Giarenis I; Robinson D; Cardozo L Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339 [TBL] [Abstract][Full Text] [Related]
26. Overactive bladder treatments in early phase clinical trials. Colli E; Digesu GA; Olivieri L Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185 [TBL] [Abstract][Full Text] [Related]
27. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder. Nik-Ahd F; Lenore Ackerman A; Anger J Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140 [TBL] [Abstract][Full Text] [Related]
28. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist]. Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434 [TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815 [TBL] [Abstract][Full Text] [Related]
30. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757 [TBL] [Abstract][Full Text] [Related]
31. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225 [TBL] [Abstract][Full Text] [Related]
32. Effects of Pelvic Floor Muscle Training on Sexual Dysfunction, Sexual Satisfaction of Partners, Urinary Symptoms, and Pelvic Floor Muscle Strength in Women With Overactive Bladder: A Randomized Controlled Study. Celenay ST; Karaaslan Y; Ozdemir E J Sex Med; 2022 Sep; 19(9):1421-1430. PubMed ID: 35934663 [TBL] [Abstract][Full Text] [Related]
33. Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management. Marcelissen T; Van Kerrebroeck P Neurourol Urodyn; 2018 Jan; 37(1):83-88. PubMed ID: 28631830 [TBL] [Abstract][Full Text] [Related]
34. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. Liu HT; Chen CY; Kuo HC J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884 [TBL] [Abstract][Full Text] [Related]
35. Association of symptoms with urodynamic findings in men with overactive bladder syndrome. Al-Zahrani AA; Gajewski JB BJU Int; 2012 Dec; 110(11 Pt C):E891-5. PubMed ID: 22928556 [TBL] [Abstract][Full Text] [Related]
36. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program. Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144 [TBL] [Abstract][Full Text] [Related]
37. Botulinum toxin injections for adults with overactive bladder syndrome. Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392 [TBL] [Abstract][Full Text] [Related]
38. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder. Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200 [TBL] [Abstract][Full Text] [Related]
39. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? Giarenis I; Mastoroudes H; Srikrishna S; Robinson D; Cardozo L BJU Int; 2013 Aug; 112(4):501-7. PubMed ID: 23452071 [TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]